US pharmaceutical giant AbbVie (NYSE:ABBV) last week broke ground on a new US$223 million (S$301 million) expansion of its manufacturing facility in Singapore, boosting its manufacturing capacity.
The new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network, the company said.
AbbVie’s Singapore facility, located in Singapore’s Tuas Biomedical Park, produces cutting-edge small molecules and biologics.
This article is accessible to registered users. Register for free to read more. Your free trial gives you access to his week of exclusive features, interviews, recaps, and commentary from some of the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial is over, you can subscribe here.
TRY BEFORE YOU BUY
• All the news that moves the pharmaceutical and biotech needle.
• Exclusive features, podcasts, interviews, data analysis and commentary from a global network of life science reporters.
• Receive The Pharma Letter’s daily news bulletins free forever.
become a subscriber
• Free access to industry-leading news, commentary and analysis in pharma and biotech.
• Latest information from clinical trials, conferences, M&A, licensing, financing, regulation, patents and legislation, executive appointments, commercial strategy, and financial results.
• Daily roundup of major events in pharma and biotechnology.
• Host monthly in-depth briefings on board appointments and M&A news.
• Choose from cost-effective annual packages or flexible monthly subscriptions.